The pristinamycins exhibit a strong synergistic antibacterial activity against a wide range of Gram-positive and some Gram-negative bacteria, including methicillin- and vancomycin-resistant strains. Pristinamycin is an effective, well-tolerated alternative therapeutic option in MSSA BJI, on condition that a daily dosage of 50 mg/kg is respected.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
Pristinamycin in the treatment of MSSA bone and joint infection.
Valour F, et al. J Antimicrob Chemother. 2016 Apr;71(4):1063-70. PMID: 26801082.
A Complex Signaling Cascade Governs Pristinamycin Biosynthesis in Streptomyces pristinaespiralis.
Mast Y, et al. Appl Environ Microbiol. 2015 Oct;81(19):6621-36. PMID: 26187956.
GC376 is a 3CLpro inhibitor; inhibits the replication of viruses TGEV, FIPV and PTV with IC50 values of 0.15, 0.2 and 0.15 μM.
AVex-73 hydrochloride is a Sigma-1 Receptor agonist with an IC50 of 860 nM.
Tropifexor is a novel and highly potent agonist of farnesoid X receptor (FXR).
Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyper-glycemic effect.
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.